Growth Opportunities in the Global Liquid Biopsy Market

According to a new market report published by Lucintel, the future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic & research centers. The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2027 with a CAGR of 17.9% from 2022 to 2027. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need for early detection of high precision diseases in real time.
In this market, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) are the various circulating biomarkers. On the basis of comprehensive research, Lucintel forecasts that circulating tumor DNA (ctDNA) will remain the largest segment, and it is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in the early stage.
Within the global liquid biopsy market, early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring are the major clinical application segments. Therapy selection will remain the largest clinical application segment over the forecast period as it offers various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
APAC will remain the fastest growing region over the forecast period due to a rising incidence of cancer, rising non-invasive treatment, and improving healthcare infrastructure.
Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector. Guardant, Bio-Rad Laboratories, Qiagen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher are among the major players in the liquid biopsy market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global liquid biopsy market by product, circulating biomarker, application, clinical application, end use, and region, and has compiled a comprehensive research report titled “Growth Opportunities in the Global Liquid Biopsy Market 2022-2027: Trends, Forecast, and Opportunity Analysis.” The Lucintel report serves as a catalyst for growth strategy by providing comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global liquid biopsy market by product, circulating biomarker, application, clinical application, end use, and region, as follows:
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.
This report addresses the following key questions:
Q.1 What are some of the most promising growth opportunities for the global liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges, and business risks in this market?
Q.5 What are the business risks and competitive threats in this market?
Q.6 What are the emerging trends in this market and the reasons behind them?
Q.7 What are some of the changing demands of customers in the market?
Q.8 What are the new developments in the market and which companies are leading these developments?
Q.9 Who are the major players in this market? What strategic initiatives are being taken by key players for business growth?
Q.10 What are some of the competing products in this market and how big of a threat do they pose for loss of market share by product substitution?
Q.11 What M & A activity has occurred in the last 5 years?